Company intelligence / Profile preview

Nectin Therapeutics

Ownership: Private
Development stage: Other

Overview

Nectin Therapeutics has launched a global Phase 1 clinical trial for its first-in-class anti-PVR antibody NTX1088, targeting advanced solid tumors. The company’s pipeline also includes preclinical ADCs designed to overcome resistance to current immune checkpoint inhibitors. Early results focus on safety and dose escalation/expansion; efficacy data are pending.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

10 assets

NTX-1088

9 more assets in the full pipeline.

Partnerships

Merck/MSD — clinical trial collaboration agreement for NTX1088 with MD Anderson Cancer Center and MSD/MerckImmunome — licensed novel antibodies to Immunome in July 2024

Beyond the preview

Go deeper on Nectin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nectin Therapeutics.